KEY POINTS
- This retrospective single-center study from Tata Memorial Centre, Mumbai, included 54 patients with de novo metastatic nasopharyngeal carcinoma treated between 2013 and 2024 with induction chemotherapy followed by definitive locoregional radiotherapy (LRRT). Seventeen patients (31.5%) additionally received curative-intent metastasis-directed therapy (MDT), while 37 did not. Median age was 41.5 years, 74.1% were male, and 30/54 (55.6%) had oligometastatic disease, defined as ≤5 metastatic lesions involving ≤2 organs.
- All patients underwent induction chemotherapy followed by definitive irradiation of the nasopharynx and bilateral neck. The median number of induction cycles was three, predominantly using gemcitabine–platinum, docetaxel–cisplatin–5-fluorouracil, or taxane–platinum regimens. Among 53 patients with response data, 94.3% achieved complete or partial response. Definitive IMRT delivered a median 66 Gy, with 50/54 patients (92.6%) receiving ≥66 Gy, and 53/54 (98.1%) receiving concurrent chemotherapy. MDT consisted of radiotherapy to metastatic sites in 15 patients and radiofrequency ablation in two; 14 of 15 radiotherapy-based MDT courses began before or during LRRT.
- Metastasis-directed therapy was associated with substantially better disease control. At a median follow-up of 27 months, two-year recurrence-free survival (RFS) was 81.9% with MDT versus 28.2% without MDT (p<0.001), an absolute difference of 53.7 percentage points. Two-year distant recurrence-free survival (DRFS) was 93.8% versus 35.0% (p<0.001). Recurrence occurred in 3/17 patients (17.6%) receiving MDT compared with 26/37 (70.3%) without MDT, although these crude comparisons reflect nonrandom treatment selection.
- Overall survival was numerically higher with MDT, but adjusted analysis did not establish an independent survival benefit. Two-year OS was 92.3% with MDT versus 55.2% without (log-rank p=0.0069), while median OS for the entire cohort was 36 months. In multivariable Cox regression adjusting for metastatic burden, induction chemotherapy response, and adjuvant chemotherapy, MDT remained associated with improved RFS (HR 0.27, 95% CI 0.08–0.98; p=0.047). However, the corresponding adjusted OS association was not statistically significant (HR 0.25, 95% CI 0.06–1.13; p=0.072).
- The RFS association persisted in several analyses addressing treatment timing and confounding. In a two-month landmark analysis involving 50 patients, MDT was associated with improved RFS (HR 0.26, 95% CI 0.075–0.90; p=0.033). Treating MDT as a time-varying covariate yielded HR 0.17 (95% CI 0.040–0.76; p=0.020). An exploratory inverse-probability-weighted analysis also favored MDT (HR 0.09, 95% CI 0.01–0.52), but its effective sample size was only 24.9 patients, indicating substantial statistical instability.
- Metastatic burden strongly influenced treatment selection and outcomes. Oligometastatic disease was present in 15/17 MDT-treated patients (88.2%), compared with 15/37 patients (40.5%) without MDT (p=0.0029). Patients with oligometastatic disease had higher two-year RFS (59.2% vs 27.8%; p=0.007) and DRFS (69.0% vs 31.4%; p=0.004) than those with polymetastatic disease. Within the 30-patient oligometastatic subgroup, two-year OS was 91.7% with MDT versus 63.6% without (p=0.03), although the subgroup was too small to establish a treatment effect independent of selection.
- Exploratory biomarkers and toxicity findings provided additional clinical context. Detectable plasma EBV DNA after induction chemotherapy was associated with inferior distant disease control, while post-LRRT PET SUVmax >4.0 was associated with worse locoregional control. Treatment-related toxicity was generally dominated by grade 1–2 mucositis, dermatitis, and dysphagia, with late xerostomia and subcutaneous fibrosis; no grade ≥3 xerostomia was reported. The study did not provide a controlled comparison of MDT-specific toxicity, and its small, selected cohort, variable systemic treatments, and limited contemporary immunotherapy exposure prevent causal conclusions.
CLINICAL TAKEAWAY
Adding metastasis-directed therapy to induction chemotherapy and definitive locoregional radiotherapy was associated with markedly improved recurrence-free and distant disease control in selected patients with de novo metastatic nasopharyngeal carcinoma, particularly those with limited metastatic burden. However, preferential MDT selection for oligometastatic patients and residual confounding prevent attribution of the survival differences to MDT itself, and prospective randomized evaluation is needed before routine treatment intensification can be recommended.